Compare FATE & CBUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FATE | CBUS |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Agricultural Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.6M | 142.7M |
| IPO Year | 2013 | 2017 |
| Metric | FATE | CBUS |
|---|---|---|
| Price | $2.35 | $1.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 2 |
| Target Price | $4.10 | ★ $9.00 |
| AVG Volume (30 Days) | ★ 1.1M | 89.8K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 29.88 | ★ 74.33 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,646,000.00 | $3,639,000.00 |
| Revenue This Year | N/A | $112.72 |
| Revenue Next Year | N/A | $83.18 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.94 | $1.09 |
| 52 Week High | $3.23 | $4.19 |
| Indicator | FATE | CBUS |
|---|---|---|
| Relative Strength Index (RSI) | 39.71 | 28.95 |
| Support Level | $2.27 | $1.19 |
| Resistance Level | $2.55 | $1.63 |
| Average True Range (ATR) | 0.11 | 0.07 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 0.00 | 4.55 |
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.